SLC5A2 and sarcopenia: However, drugs for diabetes, such as the SGLT2 inhibitor and insulin, which can affect the progression of sarcopenia or the loss of muscle mass, revealed that there was no relationship between the usage of such drugs and sarcopenic risk in the present study.